3 Stocks under discussion – BIT, MXC and SAS

3 stocks under discussion

After the stock markets ended more or less flat today, three stock that came under discussion are from health care and telecommunication sector. Let’s have a look at them:

BIOTRON LIMITED (ASX: BIT) – Biotron has recently secured $4.7 million underwriting agreement with CPS capital group Pvt. Ltd. The company posted a net loss after tax from ordinary activities down by 48.48 percent to $1,593,645. Also, at the end of June 30, 2018, the cash and cash equivalents are of $1,543,002 which is lower compared to the cash of $1,987,384 in 2017. The EPS is around -0.004 AUD which is reflecting on the losses made by the company. Result of which the directors do not recommend dividends to be paid or declared for the financial year. The stock of Biotron Limited has risen 13.725% on the back of agreement and traded at a market price of $0.290, as at October 19, 2018, and over the last twelve months period it has witnessed a performance change of a staggering 1553.62%.  

MGC PHARMACEUTICALS LTD (ASX: MXC) – The transaction will see MXC hold a material equity holding in CannaGlobal, following the sale of MGC Derma to CannaGlobal on the terms as announced on 27 September and 4 October 2018. Though health experts see an even bigger opportunity, the company expects to generate in excess of $1 million in annualized revenue. CannEpil is an orally-administered medical cannabis treatment, for refractory epilepsy or drug-resistant, which accounts for about 30 percent of all epilepsy cases. As at June 30, 2018, the revenue has increased significantly from $120,242 in 2017 which is up by 146% to $296,811. At the end of the financial year, the cash and cash equivalents has been $9.86 million with no debt representing healthy balance sheet. The stock of MGC has fallen -4.225% and traded at a market price of $0.068, as at October 19, 2018, and over the last twelve months period it has witnessed a performance change of 86.84%.

SKY AND SPACE GLOBAL LTD (ASX: SAS) – The income has marginally gone up from $54,376 in 2017 to $71,454 in 2018. However, the company posted a net loss of $8.3 million compared to the loss of $14.8 million in 2017. The result of which dividends have not been paid or declared for payment during the financial year which is also represented by the negative earnings per share (EPS) of (0.49) which has improved compared to (1.10) last year. As at June 30, 2018 the company has a cash at bank of approximately $8.9 million compared to the 2017 cash of $9.94 million with no debt facility pending. The stock of SAS had a flat daily price change and traded at a market price of $0.057, as at October 19, 2018, and over the last twelve months period it has witnessed a performance change of -64.38%.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

Sponsored ad by Kalkine

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here